News Focus
News Focus
icon url

MrW

10/30/14 5:22 PM

#76077 RE: TheDane #76076

Correct! (I think)
icon url

Ovidius

10/30/14 5:27 PM

#76085 RE: TheDane #76076

I agree that this is a very good thing, being in a place of strength is important during these next critical months.

The offerings will of course be priced according to need and market, no more aspire, which also is a good thing.

There will be news coming to off set any short sightedness by some shareholders. Probably next week.
icon url

drupac

10/30/14 5:31 PM

#76089 RE: TheDane #76076

"There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator. Biostatistics are being reviewed and will be made available to shareholders over the coming weeks."

Atleast we get a timeline when the data will be released